Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-159 |
Sentence |
denotes |
Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity. |
T1 |
0-159 |
Sentence |
denotes |
Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity. |
T2 |
160-295 |
Sentence |
denotes |
Receptor for advanced glycation end products (RAGE) is a pattern recognition receptor that binds a variety of pro-inflammatory ligands. |
T2 |
160-295 |
Sentence |
denotes |
Receptor for advanced glycation end products (RAGE) is a pattern recognition receptor that binds a variety of pro-inflammatory ligands. |
T3 |
296-397 |
Sentence |
denotes |
Its soluble form, sRAGE, can compete for ligand binding and thereby have an anti-inflammatory effect. |
T3 |
296-397 |
Sentence |
denotes |
Its soluble form, sRAGE, can compete for ligand binding and thereby have an anti-inflammatory effect. |
T4 |
398-545 |
Sentence |
denotes |
We have recently reported that sRAGE also exerts pro-inflammatory and chemotactic properties suggesting a dual role for sRAGE in immune modulation. |
T4 |
398-545 |
Sentence |
denotes |
We have recently reported that sRAGE also exerts pro-inflammatory and chemotactic properties suggesting a dual role for sRAGE in immune modulation. |
T5 |
546-660 |
Sentence |
denotes |
Our present aim was to analyse the immunomodulatory properties of sRAGE in vivo with respect to acquired immunity. |
T5 |
546-660 |
Sentence |
denotes |
Our present aim was to analyse the immunomodulatory properties of sRAGE in vivo with respect to acquired immunity. |
T6 |
661-787 |
Sentence |
denotes |
Naive mice were treated intra-peritoneally with sRAGE and cells from peritoneal lavage, spleens and bone marrow were examined. |
T6 |
661-787 |
Sentence |
denotes |
Naive mice were treated intra-peritoneally with sRAGE and cells from peritoneal lavage, spleens and bone marrow were examined. |
T7 |
788-958 |
Sentence |
denotes |
Mice treated with sRAGE displayed an increased leucocyte count in the peritoneal cavity, enlarged spleens and increased cellularity compared with vehicle-treated animals. |
T7 |
788-958 |
Sentence |
denotes |
Mice treated with sRAGE displayed an increased leucocyte count in the peritoneal cavity, enlarged spleens and increased cellularity compared with vehicle-treated animals. |
T8 |
959-1152 |
Sentence |
denotes |
Furthermore, sRAGE-treated mice had a significantly increased frequency and number of CD19(+) B cells in spleen and a reduced frequency of CD19(+) B cells in bone marrow compared with controls. |
T8 |
959-1152 |
Sentence |
denotes |
Furthermore, sRAGE-treated mice had a significantly increased frequency and number of CD19(+) B cells in spleen and a reduced frequency of CD19(+) B cells in bone marrow compared with controls. |
T9 |
1153-1447 |
Sentence |
denotes |
Functionally, splenocytes from sRAGE-treated mice showed elevated IgG production and up to a four-fold increased IgM secretion compared with control animals and produced significantly higher levels of interleukin-10, interferon-γ and interleukin-6 in response to lipopolysaccharide stimulation. |
T9 |
1153-1447 |
Sentence |
denotes |
Functionally, splenocytes from sRAGE-treated mice showed elevated IgG production and up to a four-fold increased IgM secretion compared with control animals and produced significantly higher levels of interleukin-10, interferon-γ and interleukin-6 in response to lipopolysaccharide stimulation. |
T10 |
1448-1655 |
Sentence |
denotes |
Our results suggest that sRAGE has immunomodulatory properties, since intra-peritoneal administration of sRAGE into healthy mice leads to rearrangements in cellular composition in the bone marrow and spleen. |
T10 |
1448-1655 |
Sentence |
denotes |
Our results suggest that sRAGE has immunomodulatory properties, since intra-peritoneal administration of sRAGE into healthy mice leads to rearrangements in cellular composition in the bone marrow and spleen. |
T11 |
1656-1754 |
Sentence |
denotes |
Moreover, the administration of sRAGE directs B cells into the spleen and towards differentiation. |
T11 |
1656-1754 |
Sentence |
denotes |
Moreover, the administration of sRAGE directs B cells into the spleen and towards differentiation. |
T12 |
1755-1845 |
Sentence |
denotes |
Our novel findings indicate that sRAGE exerts an effect on the cells of adaptive immunity. |
T12 |
1755-1845 |
Sentence |
denotes |
Our novel findings indicate that sRAGE exerts an effect on the cells of adaptive immunity. |